Facebook
Twitter
LinkedIn
Forward
The Pharmacotherapy of Alcohol and Opioid Use Disorders (Recorded at Pri-Med Midwest)
In the U.S., about 15.1 million people have an alcohol use disorder and about 4.8 million misuse opioids. This session focuses on the pharmacotherapy of alcohol and opioid use disorders. The faculty will describe and contrast naltrexone and acamprosate treatments for alcohol use disorder and discuss the use of buprenorphine/naloxone to treat opioid use disorder.
Learning Objectives
- Describe and contrast the mechanism of action of naltrexone and acamprosate in the treatment of alcohol use disorder
- Use buprenorphine/naloxone to treat opioid use disorder
Additional Information
Petros Levounis, MD, MA
Chair, Department of Psychiatry
Rutgers New Jersey Medical Center
Newark, NJ
Disclosures
The following relevant financial relationships have been disclosed by faculty:
Petros Levounis, MD, MA
No financial relationships disclosed.
Non-faculty contributors involved in the planning, development, editing, and review of the content have disclosed no relevant financial relationships.
AMA PRA Category 1 Credits™
Accreditation Statement
pmiCME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation Statement
pmiCME designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
This course is offered through Pri-Med.
To take this course you will be redirected to Pri-Med's website. You must login or create an account with Pri-Med in order to complete this activity.
Mocingbird works to provide curated, high quality content to our users. Have a suggestion? Want to partner with us? Get in touch!